Cargando…
Torin2 inhibits the EGFR-TKI resistant Non-Small Lung Cancer cell proliferation through negative feedback regulation of Akt/mTOR signaling
It is known that mammalian target of rapamycin (mTOR) signaling plays an important role in NSCLC cells proliferation. Torin2 is a second-generation ATP-competitive inhibitor which is selective for mTOR activity. In this study, we investigated whether torin2 was effective against lung cancer cells, e...
Autores principales: | Hu, Yi, Zhang, Ji, Liu, Qun, Ke, Mingyao, Li, Jiurong, Suo, Wenhao, Guo, Weixi, Ma, Aiping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7477446/ https://www.ncbi.nlm.nih.gov/pubmed/32913468 http://dx.doi.org/10.7150/jca.37417 |
Ejemplares similares
-
Rapamycin-resistant and torin-sensitive mTOR signaling promotes the survival and proliferation of leukemic cells
por: Park, Seohyun, et al.
Publicado: (2016) -
Targeting the mTOR pathway using novel ATP-competitive inhibitors, Torin1, Torin2 and XL388, in the treatment of glioblastoma
por: Amin, Anubhav G., et al.
Publicado: (2021) -
PI3K-AKT-mTOR pathway alterations in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus everolimus combination therapy
por: Fang, Wenfeng, et al.
Publicado: (2020) -
Collagen type I induces EGFR‐TKI resistance in EGFR‐mutated cancer cells by mTOR activation through Akt‐independent pathway
por: Yamazaki, Shota, et al.
Publicado: (2018) -
Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1
por: Francipane, Maria Giovanna, et al.
Publicado: (2013)